Presage Biosciences is an oncology company that is pioneering an entirely novel approach to evaluating patient response to drugs in clinical trials.
Using our patented CIVO™ technology, we deliver pharmacologically appropriate concentrations of multiple drugs to different regions of a tumor – while the tumor is still in the patient. Observing molecular and cellular responses to drugs and combinations in an authentic human tumor gives us a far greater understanding of tumor biology, directly embodying a patient’s own immune system, tumor microenvironment, heterogeneity and genetic background. It is Presage’s mission to use this understanding to revolutionize the way drugs are selected, tested and targeted, with the goal of providing more effective treatments to patients with cancer.
Through research alliances, Presage collaborates with biopharmaceutical companies to discover new, effective drug combinations and to identify drug sensitivity and resistance in target patient populations. Presage also is actively developing in-licensed drug candidates and plans to employ CIVO™ to advance a portfolio of promising oncology therapies to the clinic.
November 24, 2015 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that it has in-licensed voruciclib, its first clinical stage drug program. Voruciclib is an oral CDK inhibitor that has been in clinical development for cancer indications and will be developed in combination with other standard of care agents.
November 24, 2015 | Seattle, Wash. Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Tachi Yamada and Christoph Lengauer to its board of directors.